x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012764
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe920 of human PRSS15/LONP1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | LONP1 |
| UniProt No. | P36776 |
| Gene ID | 9361 |
| Gene Description | PRSS15/LONP1 is an ATP-dependent serine protease that selectively degrades misfolded, misassembled, or damaged proteins in mitochondrial matrix. PRSS15/LONP1 is induced by hypoxic, proteotoxic, and endoplasmic reticulum stress to support cell survival. It has been reported that PRSS15/LONP1 inducibility is decreased during aging and chronic stress. PRSS15/LONP1 is found to be substantially elevated in lymphoma cells compared to resting or activated B cells, and knock-down or inhibition of PRSS15/LONP1 induces apoptosis in lymphoma cells. Mutation in PRSS15/LONP1 is associated with CODAS syndrome, a multi-system developmental disorder characterized by cerebral, ocular, dental, auricular, and skeletal anomalies. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
